Sagimet Biosciences, Inc. Class A (SGMT) AI Stock Analysis

• Market Cap: $161.52M
• Dividend Yield: N/A
• Average Volume (3M): 513.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.93
• Revenue Growth: N/A
• EPS Growth: -38.23%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.29
• Shares Outstanding: 31,001,108
• 10 Day Avg. Volume: 304,405
• 30 Day Avg. Volume: 513,420
• PEG Ratio: -0.42
• Price to Book (P/B): 1.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.19
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -2.22
• 1Y Price Target: $26.00
• Price Target Upside: 399.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -1.91
• Revenue Forecast (FY): $300.00K

• Rating: 50 Neutral
• Price Target: $5.50 ▲(5.57% Upside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is primarily held back by weak operating fundamentals (minimal revenue, large losses, and ongoing cash burn) despite a strengthened, low-debt balance sheet. Technical indicators suggest neutral-to-soft momentum, while valuation is difficult to support due to losses and no dividend. Offsetting factors include multiple positive, pipeline-related corporate updates that improve the clinical/strategic outlook.

Positive Factors

Low leverage / strong balance sheet

Very low debt and a materially strengthened equity base (~$111.4M in 2025) reduce financial risk and provide structural optionality. This capital base supports multi-year clinical programs, partnership execution and R&D spend without immediate insolvency risk, improving strategic flexibility.

Advancing MASH combo into Phase 2

Completion of combination PK and a planned Phase 2 proof-of-concept in F4 MASH marks a structural clinical advancement. Targeting F4 cirrhosis addresses an unmet, durable market need; a successful Phase 2 would materially de-risk the program and enable later-stage commercialization pathways.

Dermatology validation & partner NDA

Partner-reported positive Phase 3 results and NMPA NDA acceptance provide external validation of the FASN approach and a non-dilutive commercialization route in China. This diversifies development risk and could yield milestones, supporting long-term pipeline credibility and regional revenue potential.

Negative Factors

Lack of sustainable revenue

The company lacks a recurring revenue base, leaving operations fully dependent on financing and partner deals. Without sustained product sales, SGMT must convert clinical success into commercial traction; until then, revenue uncertainty constrains self-sufficiency and long-term margins.

Persistent and rising cash burn

Consistently negative operating and free cash flow, with cash burn rising year-over-year, increases funding dependence risk. Even with ~ $113M liquidity noted, ongoing Phase 2/3 programs and R&D will pressure runway and likely require future non-dilutive deals or dilutive financing.

Large net losses / negative returns

Substantial annual losses and deeply negative ROE indicate investments have yet to translate into profitable operations. Persistent negative returns can limit strategic choices, raise scrutiny on capital allocation, and increase the likelihood of future financing that dilutes existing shareholders.

Sagimet Biosciences, Inc. Class A Business Overview & Revenue Model

Company Description

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

How the Company Makes Money

null

Sagimet Biosciences, Inc. Class A Financial Statement Overview

Summary

Overall profile is mixed: the balance sheet is strong with very low leverage and positive equity, but the business has effectively no sustained revenue, large ongoing net losses, and continued negative operating/free cash flow indicating meaningful funding dependence.

Income Statement

Revenue is effectively absent in most years (including 2024 and 2025), and losses remain large and persistent (net loss of about $51.0M in 2025 vs. $45.6M in 2024). Profitability is weak with consistently negative operating results, indicating the business is still in a heavy investment/burn phase. A positive point is that 2023 showed some revenue ($2.0M), but it has not yet translated into a sustained top-line trajectory.

Balance Sheet

Leverage is very low (total debt only ~$0.08M in 2025; debt-to-equity near zero), which materially reduces financial risk. Equity and assets strengthened versus earlier years, with stockholders’ equity positive at ~$111.4M in 2025 (after being negative in 2020–2022), suggesting meaningful recapitalization or funding support. The key weakness is that returns remain negative (return on equity around -46% in 2025), reflecting ongoing losses despite the improved capital base.

Cash Flow

Cash generation is weak with consistently negative operating cash flow and free cash flow (about -$45.7M in 2025 vs. -$42.4M in 2024), indicating ongoing cash burn. Cash burn has generally trended higher from 2023 to 2025, which raises funding dependence risk. A modest positive is that free cash flow improved year-over-year in 2025 versus 2024 (as reflected by positive free cash flow growth), but it remains deeply negative overall.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	2.00M	0.00	0.00
Gross Profit	0.00	0.00	2.00M	0.00	0.00
EBITDA	-56.89M	-45.57M	-30.74M	-31.05M	-23.72M
Net Income	-51.04M	-45.57M	-27.88M	-30.50M	-24.44M
Balance Sheet
Total Assets	116.48M	160.26M	96.72M	33.03M	59.03M
Cash, Cash Equivalents and Short-Term Investments	113.12M	151.25M	94.90M	32.34M	56.73M
Total Debt	78.00K	78.00K	65.00K	211.00K	348.00K
Total Liabilities	5.10M	4.45M	5.65M	219.98M	217.29M
Stockholders Equity	111.38M	155.81M	91.06M	-186.95M	-158.26M
Cash Flow
Free Cash Flow	-45.65M	-42.44M	-23.77M	-24.49M	-21.71M
Operating Cash Flow	-45.65M	-42.44M	-23.77M	-24.49M	-21.71M
Investing Cash Flow	4.56M	-61.68M	12.58M	-32.01M	0.00
Financing Cash Flow	275.00K	104.82M	86.17M	-73.00K	9.74M

Sagimet Biosciences, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMT, the sentiment is Negative. The current price of 5.21 is below the 20-day moving average (MA) of 5.51, below the 50-day MA of 5.74, and below the 200-day MA of 7.04, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 42.11 is Neutral, neither overbought nor oversold. The STOCH value of 37.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGMT.

Sagimet Biosciences, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDTX	59 Neutral	$120.79M	-6.32	17.78%	―	―	―
AVIR	57 Neutral	$486.00M	-1.84	-46.34%	―	―	14.33%
TRDA	55 Neutral	$485.83M	-2.96	-39.83%	―	-71.42%	-248.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SGMT	50 Neutral	$161.52M	-3.75	-40.85%	―	―	-38.23%
CDXS	50 Neutral	$146.30M	-3.23	-114.26%	―	-17.87%	14.42%
CABA	50 Neutral	$294.57M	-1.33	-107.14%	―	―	-17.21%

Sagimet Biosciences, Inc. Class A Corporate Events

Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress

Sagimet Biosciences reported its fourth-quarter and full-year 2025 results on March 11, 2026, highlighting clinical progress across its MASH and acne portfolios and solid liquidity of $113.1 million in cash, cash equivalents and marketable securities at year-end. The company completed a Phase 1 pharmacokinetic trial of denifanstat combined with thyroid hormone receptor beta agonist resmetirom with no safety signals and plans to advance this combination into a Phase 2 proof-of-concept trial in F4 MASH in the second half of 2026, while continuing a Phase 1 trial of acne-targeted FASN inhibitor TVB-3567.

In parallel, Sagimet strengthened its combination strategy via a global, exclusive license to innovative resmetirom active pharmaceutical ingredient forms from TAPI and benefited from partner Ascletis’ positive 52-week Phase 3 acne data and China NMPA acceptance of a New Drug Application for denifanstat in moderate to severe acne. Financially, 2025 research and development expenses were $39.1 million and net loss widened to $51.0 million, reflecting an intensified development program that could enhance the company’s position in high-need liver and dermatology markets if upcoming Phase 2 trials and regulatory pathways progress as planned.

The most recent analyst rating on (SGMT) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.

Sagimet Biosciences Reports Positive Phase 3 Acne Data

On February 2, 2026, Sagimet Biosciences reported that its Chinese license partner Ascletis Pharma released positive topline data from a 52-week Phase 3 program of denifanstat (ASC40) in patients with moderate to severe acne, including an open-label extension trial evaluating long-term safety. In the multi-center ASC40-304 study, 240 patients who had completed a prior 12-week randomized Phase 3 trial received once-daily oral denifanstat 50 mg for up to 40 additional weeks; treatment was generally well tolerated, with only mild to moderate treatment-related adverse events, low rates of common side effects such as dry eye and dry skin, no denifanstat-related serious adverse events, and no permanent discontinuations attributed to the drug. Patients experienced further improvements across all key efficacy measures—including Investigator’s Global Assessment response rates and reductions in total and inflammatory lesion counts—beyond those seen at 12 weeks, strengthening the clinical case for FASN inhibition as a novel mechanism in acne and supporting Sagimet’s broader strategy to advance denifanstat and next-generation FASN inhibitors across dermatologic and metabolic indications.

The most recent analyst rating on (SGMT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.

Sagimet Highlights Positive MASH Combo Data and Pipeline Progress

On 18 December 2025, Sagimet Biosciences updated its investor presentation and issued a press release reporting positive results from a Phase 1 pharmacokinetic trial evaluating a combination of its FASN inhibitor denifanstat with the thyroid hormone receptor beta agonist resmetirom, a pairing supported by preclinical evidence of synergistic effects in MASH. The refreshed materials highlight denifanstat’s progress in MASH, where a Phase 2b trial previously met histology primary and multiple secondary endpoints and the program has FDA Breakthrough Therapy designation with Phase 3 readiness, as well as the completion of a Phase 1 hepatic impairment study and the new Phase 1 combination PK data that pave the way for a planned Phase 2 trial in MASH cirrhosis (F4) in the second half of 2026. The company also underscores growing momentum in dermatology, with licensee Ascletis having reported that a Phase 3 acne trial of denifanstat in China met all primary and secondary endpoints and that a new drug application for moderate to severe acne was accepted by China’s NMPA in December 2025, while Sagimet advances TVB-3567 in a first-in-human Phase 1 acne study, collectively strengthening its clinical pipeline and reinforcing its strategic positioning in metabolic and inflammatory diseases.

The most recent analyst rating on (SGMT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.

Sagimet Biosciences enters global license agreement with TAPI

Sagimet Biosciences Inc. announced its entrance into a license agreement with TAPI Technology & API Services, a subsidiary of Teva Pharmaceutical Industries Ltd., on December 17, 2025. This collaboration grants Sagimet a global, exclusive license to TAPI’s innovative resmetirom active pharmaceutical ingredient (API), supporting the development of a fixed-dose combination (FDC) product featuring denifanstat and resmetirom. The program aims to address critical unmet needs for cirrhosis patients affected by F4-stage MASH. This move marks a significant step forward for Sagimet’s research and development efforts as it aligns with preclinical data showing synergy in treating liver diseases, positioning Sagimet for further advancement in the field.

The most recent analyst rating on (SGMT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.